Cellectar Biosciences, Inc.
Cellectar Biosciences develops drugs for cancer treatment. Its lead candidate, CLR 131, is in Phase 2 studies for B-cell malignancies and other lymphomas. Additional studies include pediatric solid tumors/lymphomas/malignant brain tumors and head and neck cancer. CLR 1900 is a preclinical PDC chemotherapeutic program for solid tumors. The company collaborates with Orano Med and LegoChemBio. Founded in 2002, its headquartered in Florham Park, New Jersey.
Overview
Strengths
- Valued below its Biotechnology peers: EV/EBITDA 0.3x vs. a median of 15.6x.
- Cheaper than its own history: EV/EBITDA 0.3x vs. a historical average of 83.3x.
- Conservative leverage: net debt is only 0.5x EBITDA.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 10.9% in each of the last 5 years.
- Shareholder dilution: the share count has grown by 138.4% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- Earnings quality red flag: reported profit exceeds operating cash flow by 8.9% of total assets.
Key Financial Data